Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Jeff Ackerman Just Put (VNRX) On This Morning's Early Watchlist
—Wednesday, February 25, 2026. Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
Full Coverage Is Starting Right Now—Take A Look At (VNRX)
While It's Still Early…
February 25, 2026
Countdown is On | See Why (VNRX) is Topping Today's Watchlist Right Now
Dear Reader, After watching yesterday's profile rip for an approximate 36% overnight move (26% intraday), Stock News Trends is already looking at the next name lighting up our screen this morning—Wednesday, February 25, 2026. 
Diagnostics is quietly entering its next chapter—but the breakout isn't coming from bigger machines or more complexity. It's coming from smarter signal extraction off something as simple as a routine blood draw. While most eyes have been elsewhere, VolitionRx Limited (VNRX) has been building an epigenetics platform with real-world scale in mind. After years of methodical R&D, (VNRX) now looks like it's crossing into a higher-stakes execution phase—where adoption, distribution, and momentum start to matter as much as the science. And the headlines aren't slowing down. In its latest press release, (VNRX) announced a new distribution partner in Japan for its Nu.Q® Discover assays—expanding reach in a major life-science research market and reinforcing the company's push to broaden adoption across its research pillar. Recently, (VNRX) showed what it can do when attention shows up — making an approximate 72% move in under two weeks, from around $0.22 on December 29, 2025 to $0.38 on January 8, 2026. Since then, (VNRX) appears to be flying under the radar at these levels, and recent near-term RSI levels suggest it has slipped into what some consider "oversold territory" — a setup that can sometimes precede a potential trend reversal if momentum starts to rotate back in. Taken together, it's the kind of quiet setup that can flip fast — and it's exactly why (VNRX) is starting to demand a closer look right here. After more than a decade refining its science and platform, recent milestones — along with continued progress on intellectual property and partner discussions — suggest the rollout is beginning to take shape. That's why (VNRX) just hit our radar… and why it's topping our watchlist this morning—Wednesday, February 25, 2026.
And (VNRX)'s progress is not going unnoticed. Several analysts covering the company continue to point to what they see as a meaningful gap between its current valuation and its long-term commercial potential. Analyst Targets Suggest As Much As 1,400% Upside Potential
Analysts maintain a significantly bullish outlook on (VNRX) compared to its recent $.20 range. Keep reading to see why we're so excited to be highlighting (VNRX) right now. A Decade in the Making: The Technology Powering (VNRX)
VolitionRx Limited (VNRX) is a multi-national epigenetics company dedicated to saving lives through the earlier detection of disease. Headquartered in Henderson, Nevada, with significant operations in Belgium, the company has spent over ten years mastering the science of Nucleosomics™. Their patented technology focuses on isolating and analyzing circulating nucleosomes—small segments of chromosomes—that are released into the blood when cells are damaged or diseased. The company's primary platform, Nu.Q®, is designed to be a simple, routine, and affordable blood test that can be integrated into existing clinical workflows. Unlike traditional biopsies that are often invasive and expensive, (VNRX) offers a liquid biopsy solution that provides a window into a patient's health at a molecular level. Their reach extends across human and veterinary medicine, with products like Nu.Q® Vet already available in over 20 countries through major partnerships. In late 2025, (VNRX) reached a pivotal commercial milestone by announcing the first sale of its Nu.Q® Cancer assays for clinical certification in France. This marks the transition of their technology from the laboratory to routine clinical use in a major European hospital network. Furthermore, the company recently solved a major "needle in a haystack" problem in liquid biopsy, achieving a massive 180-fold (18,000%) enrichment of tumor DNA, which could significantly improve the accuracy of early-stage cancer detection. Latest Company Updates: New Headlines Driving Momentum
Nu.Q® Vet Feline data: Detected 80%+ of feline lymphomas at 100% specificity (no false positives); peer-review publication could unlock a $5M milestone; Nu.Q® Vet Canine already in 20+ countries. Funding update: $2.0M amended institutional funding with a convertible note + 5-year warrant structure; repayments begin six months after issuance; resale registration due within 30 days of closing. Access expanding: Two new lab providers—Midwest Veterinary Laboratory (all 50 U.S. states starting Feb 2026) and Bioguard (via its Taiwan/China diagnostic center). Nu.Q® Discover in Japan: New non-exclusive distributor (MBL) expands Nu.Q® Discover reach in Japan; Discover now serves ~100 global clients including major pharma/diagnostic groups, with some programs in late-stage trials; TAM for relevant companion diagnostics just under $1B, and management cited strong 2025 growth with expectations to continue in 2026—plus potential longer-term diagnostic pathway groundwork in Japan. Why These Two Markets Could Drive (VNRX)'s Next Phase
The market for early disease detection is immense, and (VNRX) is targeting some of the most burdensome conditions in modern medicine. Sepsis alone accounts for approximately one in five deaths globally, and its late detection leads to severe morbidity and high healthcare costs. According to recent business reviews, (VNRX) identifies a $2.8B Total Addressable Market (TAM) for early sepsis detection and management. The inclusion of the Nu.Q® NETs assay in France's "DETECSEPS" program—a real-world evaluation of early sepsis detection—positions Volition to address a critical gap in emergency care. By distinguishing sepsis from non-infectious inflammation, this technology could help clinicians intervene hours earlier, potentially saving countless lives. In oncology, the scope is even larger. (VNRX) estimates the annual TAM for lung cancer screening and management at $2.3B, while the broader multi-cancer early detection and liquid biopsy market represents a staggering $22B annual potential within the next decade. 
By focusing on "low-cost, high-volume" testing, (VNRX) aims to capture significant share in markets traditionally dominated by expensive, complex sequencing. Building the Commercial Network: (VNRX) and Key Collaborations
(VNRX) has successfully mirrored its veterinary success in the human diagnostic space by securing agreements with healthcare leaders. In the third quarter of 2025, the company signed a research license and exclusive commercial option with Werfen, a global leader in specialized diagnostics, to investigate the clinical utility of Nu.Q® in managing Antiphospholipid Syndrome (APS). Additionally, management is currently in discussions with approximately 10 of the world's leading diagnostic companies, suggesting a steady pipeline of licensing deals that could provide upfront payments and recurring revenue. Scaling With Discipline: Inside (VNRX)'s Recent Results
Recent results highlight a company tightening its belt while scaling its reach. For Q3 2025, (VNRX) reported a 32% year-over-year revenue increase to $0.6M. More importantly, the company reduced its operating expenses by 10% and lowered its net cash usage in operations by 33% compared to the prior year. Following a public offering that secured $6.1M in net proceeds, (VNRX) has bolstered its runway to support the commercial rollout of its human diagnostic assays. The executive team, led by CEO Cameron Reynolds, continues to focus on a capital-efficient model while expanding its intellectual property moat.
7 Reasons Why (VNRX) Just Hit The Top Of This Morning's Watchlist
—Wednesday, February 25, 2026 1. Recent Momentum: Earlier this year, (VNRX) made an approximate 72% move in under two weeks, demonstrating how quickly momentum can build when demand begins to shift. 2. Oversold Territory: At current levels, (VNRX) appears to be flying under the radar, with near-term RSI readings suggesting what some consider "oversold territory" that can precede a potential trend reversal. 3. Analyst Backing: Coverage on (VNRX) includes targets that suggest 400% to 1,400% upside potential from its recent range, highlighting a wide gap between analyst models and current levels. 4. Global Expansion: Through new distribution agreements—including Japan for Nu.Q® Discover—and existing partnerships spanning 20+ countries, (VNRX) continues expanding its international footprint. 5. Commercial Transition: After more than a decade of R&D, (VNRX) is moving from validation into broader rollout, supported by reimbursement efforts, lab partnerships, and expanding assay access. 6. Large Addressable Markets: With targeted markets including sepsis ($2.8B), lung cancer screening ($2.3B), and multi-cancer early detection ($22B over the next decade), (VNRX) is positioned within sizable healthcare segments. 7. Operational Discipline: Recent results show (VNRX) growing revenue year over year while reducing operating expenses and net cash usage, signaling a focus on capital efficiency as commercialization advances. Full Coverage Is Starting Right Now—Take A Look At (VNRX)
While It's Still Early…
(VNRX) continues to check the boxes that matter when a developing story starts moving into execution. The company has been posting fresh headlines across clinical results, expanded test availability, and continued validation work in both human and animal health. After more than a decade building its platform, (VNRX) appears to be transitioning from lab-stage development into real-world rollout, supported by distribution reach already spanning 20+ countries. Add in the feline study results showing no false positives, ongoing cost discipline, and the scale of the markets it's targeting — sepsis ($2.8B), lung cancer screening and management ($2.3B), and multi-cancer early detection and liquid biopsy ($22B) within the next decade — and it's clear why it's holding our attention this morning. Analyst coverage also assigns targets that suggest roughly 400% to 1,400% upside potential from recent levels. We have all eyes on (VNRX) this morning—Wednesday, February 25, 2026. Take a look at (VNRX) while it's still early. Also, keep a lookout for my next update—it may be hitting any moment. Jeff Ackerman
Managing Editor Stock News Trends
| 
Tidak ada komentar:
Posting Komentar